Is this Diabetes Drug Class Poised for Disruption?

The Motley Fool's health care show "Market Checkup" focuses this week on diabetes, one of America's growing health care concerns. There are 2 versions of this chonic disease -- the more prevalent being type 2 diabetes, which makes up about 95% of all cases. Because of that overwhelming patient population, type 2 diabetes receives the majority of attention from big pharma companies.

Diabetes is no small problem. In 2010, one in 10 adults has diabetes, and more troubling, more than one in four senior citizens, making it the seventh leading cause of death. There are 2 million new cases in America per year, leading analysts to project spending on diabetes to approach $60 billion in just five years. And this isn't just an American problem; 370 million suffer from diabetes around the world.

In this video, health care analysts David Williamson and Max Macaluso discuss one of the prominent diabetes drug classes, highlighting both the major players and whether a new drug from Eli Lilly  (NYSE: LLY  ) will disrupt the current standard of care.

Rising health care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health care system -- and how to potentially profit from this trend -- click here for free, immediate access.

Follow David on Twitter: @MotleyDavid.

Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 07, 2013, at 10:27 AM, tgmwood2 wrote:

    Lilly realy hurt diabetes care when they quit produsing animal insulin. An a1c of 6 goes to a a1c of 11.7 with there insulin. I can imagine this government had something to do with that. I have only had diabetes since 1957. A company in the UK - Wockhardt, is the only company in the world that I know of that still produces a animal insulin. For me, it works good. Everything the vedio said was about money and nothing about actual care. This sad country has sadly went that way. Thanks, Terry

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2524658, ~/Articles/ArticleHandler.aspx, 9/28/2016 2:53:57 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 5 hours ago Sponsored by:
DOW 18,228.30 133.47 0.74%
S&P 500 2,159.93 13.83 0.64%
NASD 5,305.71 48.22 0.92%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 4:02 PM
AZN $33.61 Up +0.06 +0.18%
AstraZeneca CAPS Rating: ****
BMY $55.74 Up +0.26 +0.47%
Bristol-Myers Squi… CAPS Rating: ****
LLY $80.88 Up +1.36 +1.71%
Eli Lilly and Co. CAPS Rating: ***
NVO $43.85 Down -0.58 -1.31%
Novo Nordisk CAPS Rating: *****